(Q83533299)
Statements
The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials (English)
J-M Grouin
E Vicaut
S Jean-Alphonse
U Wahn
A Didier
O de Beaumont
A Montagut
M Le Gall